EFFECTS OF CHEMOIMMUNOTHERAPY ON THE PERIPHERAL BLOOD: INSIGHTS FROM IMMUNE MONITORING OF A PHASE IB TRIAL OF PEMBROLIZUMAB AND PACLITAXEL OR CAPECITABINE FOR TRIPLE-NEGATIVE BREAST CANCER (TNBC)

Category Primary study
JournalJOURNAL FOR IMMUNOTHERAPY OF CANCER
Year 2021
This article has no abstract
Epistemonikos ID: 668d6fc8ec1f6ddc117432253e9dc8758b7c83d6
First added on: Feb 13, 2025